CXCR4 and myelodysplastic syndrome: Consistent with previous reports [20, 21], the percentages of CXCR4(+) HSPCs were increased in four patients with MDS (median, 66.5%; range, 54.2%–88.9%; MFI median, 8305; MFI range, 5147–10,675; Figure 5B,C) who had low percentage blasts (1.1%–2.1%) in PB.